New scanning method for generating peptide derivatives, faster rational design
Posted by grinder265 in Protocols & Stacks - 5 points, 4 comments.
https://www.asiaresearchnews.com/content/novel-method-design-new-peptide-therapeutics-pioneered
Asia Research News has a piece on a "scanning and direct derivatization" protocol out of a Japanese group that lets them build and screen hundreds of peptide derivatives way faster than the old one at a time approach. The pitch is that you can map structure function relationships in days instead of months, and use that to design therapeutics with better stability or receptor selectivity.
Honestly this is the kind of upstream stuff I want to see more of. Most of what gets posted here is people stacking BPC and TB-500 and hoping for the best, but nobody's really talking about how these molecules are even being engineered now. If this method holds up it could mean the next wave of peptides are designed rationally instead of dug out of animal tissue.
Curious if anyone with a wet lab background has read the actual paper. Wonder how the derivatives compare to the parent compounds on half life and tissue targeting, or if the gains are mostly just throughput.
Comments
- tiredmira: Honestly this is the kind of upstream stuff I want to see more of too. I'm basically a bio nerd at heart so rational design gets me more excited than another stack thread 😅 From what I've seen with small protein drugs though, faster screening doesn't always translate to better molecules in vivo. You can optimize receptor binding all day and still get wrecked by first pass metabolism or poor tissue penetration. The half life and biodistribution piece is really where things fall apart. Also wor
- grinder265: Ngl that SAR gap is exactly why I’m wary of just chasing binding affinity. In my own BPC‑157 tweaks I saw half‑life drop from 4 h to 45 min when I added a polar side chain, even though receptor Kd improved. What assay did they use for metabolic stability?
- practical_dad: Yeah totally fair, the in vivo piece is where I see things fall apart too. Like you can have a gorgeous binding profile on paper and then the molecule gets chewed up in the liver in 20 minutes. PEGylation and fatty acid conjugation help but theyre not magic, and they add their own weirdness. And yeah the SAR map is only as good as your assay. If youre measuring binding affinity but not signaling bias or downstream duration, you might be optimizing for the wrong thing entirely. Thats why I like
- grinder265: Yeah the PK gap is exactly what kills me about a lot of these papers. Gorgeous in vitro data then you get one ugly IV half life number in the supplemental and everyone quietly moves on. The bias signaling point is a good one too, ngl I didnt think about that angle as much. If youre just optimizing for receptor affinity you could easily end up with a short acting agonist that fires hard then desensitizes the receptor, which is basically the opposite of what you want for something like a tissue re
Community discussion - research and educational context only. Not medical advice.